drugset
drugset / Trial / NCT05937750

A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group

NCT05937750 ↗

Phase 3 Active not recruiting 150 enrolled Hansa Biopharma AB
Non-randomizedParallel-groupOpen-labelOther

Summary

A prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort.

Timeline

Start
2023-07-03
Primary completion
2030-04-30
Completion
2030-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Imlifidase Protein / enzyme biologic — —

Indications

No indication recorded.